Global Cholangiocarcinoma Therapeutics Market 2019-2023

胆管癌治療薬の世界市場2019-2023

◆タイトル:Global Cholangiocarcinoma Therapeutics Market 2019-2023
◆商品コード:IRTNTR30865
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年2月23日
◆ページ数:117
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、胆管癌治療薬の世界市場について調査・分析し、市場概要、市場環境、胆管癌治療薬市場規模、種類別(肝内胆管癌、肝外胆管癌)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・胆管癌治療薬の世界市場概要
・胆管癌治療薬の世界市場環境
・胆管癌治療薬の世界市場動向
・胆管癌治療薬の世界市場規模
・胆管癌治療薬の世界市場:業界構造分析
・胆管癌治療薬の世界市場:種類別(肝内胆管癌、肝外胆管癌)
・胆管癌治療薬の世界市場:地域別市場規模・分析
・胆管癌治療薬の北米市場規模・予測
・胆管癌治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・胆管癌治療薬のアジア太平洋市場規模・予測
・胆管癌治療薬の主要国分析
・胆管癌治療薬の世界市場:成長要因、課題
・胆管癌治療薬の世界市場:競争環境
・胆管癌治療薬の世界市場:関連企業情報(ベンダー分析)

About this market
Cholangiocarcinoma is one of the rare types of cancers globally, as a result, the market does not have approved therapies in abundance. The dominance of these drugs is affecting the interest of new vendors to conduct research on developing novel therapies. To overcome this challenge, several research institutes are coming up with various programs to treat patients with intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. The support from the institute is also coming in the form of new chemotherapy combinations for treating both types of cholangiocarcinoma. Similarly, various other research institutions are also working on providing treatment to the patients, and the increasing support from these institutes is expected to contribute significantly to the growth of the global cholangiocarcinoma therapeutics market during the forecast period. Technavio’s analysts have predicted that the cholangiocarcinoma therapeutics market will register a CAGR of almost 6% by 2023.
Market Overview
Growing usage of combination there
The global cholangiocarcinoma therapeutics market has a limited number of treatment options, among which the most preferred treatment option is surgeries due to the lack of efficacy of therapeutics in the late stages of the disease. To overcome this, the market is witnessing an increase in the use of combination of chemotherapies to treat the disease.
Dominance of surgery
The global cholangiocarcinoma therapeutics market faces a heavy threat from surgeries, as they are currently the most preferred treatment option available to the patients. As a result, surgeries are gaining popularity for the treatment of both intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, which is expected to have a negative impact on the growth of the global cholangiocarcinoma therapeutics market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the cholangiocarcinoma therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fairly concentrated and with the presence of few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Intrahepatic cholangiocarcinoma – Market size and forecast 2018-2023
• Extrahepatic cholangiocarcinoma – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Sanofi
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market
Exhibit 08: Global market
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 18: Global cholangiocarcinoma therapeutics market pipeline
Exhibit 19: Type – Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Intrahepatic cholangiocarcinoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Intrahepatic cholangiocarcinoma – Year-over-year growth 2019-2023 (%)
Exhibit 23: Extrahepatic cholangiocarcinoma – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Extrahepatic cholangiocarcinoma – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America – Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Bristol-Myers Squibb Company – Vendor overview
Exhibit 46: Bristol-Myers Squibb Company – Business segments
Exhibit 47: Bristol-Myers Squibb Company – Organizational developments
Exhibit 48: Bristol-Myers Squibb Company – Geographic focus
Exhibit 49: Bristol-Myers Squibb Company – Key offerings
Exhibit 50: Bristol-Myers Squibb Company – Key customers
Exhibit 51: Eli Lilly and Company – Vendor overview
Exhibit 52: Eli Lilly and Company – Business segments
Exhibit 53: Eli Lilly and Company – Organizational developments
Exhibit 54: Eli Lilly and Company – Geographic focus
Exhibit 55: Eli Lilly and Company – Segment focus
Exhibit 56: Eli Lilly and Company – Key offerings
Exhibit 57: Eli Lilly and Company – Key customers
Exhibit 58: F. Hoffmann-La Roche Ltd – Vendor overview
Exhibit 59: F. Hoffmann-La Roche Ltd – Business segments
Exhibit 60: F. Hoffmann-La Roche Ltd – Organizational developments
Exhibit 61: F. Hoffmann-La Roche Ltd – Geographic focus
Exhibit 62: F. Hoffmann-La Roche Ltd – Segment focus
Exhibit 63: F. Hoffmann-La Roche Ltd – Key offerings
Exhibit 64: F. Hoffmann-La Roche Ltd – Key customers
Exhibit 65: Pfizer Inc. – Vendor overview
Exhibit 66: Pfizer Inc. – Business segments
Exhibit 67: Pfizer Inc. – Organizational developments
Exhibit 68: Pfizer Inc. – Geographic focus
Exhibit 69: Pfizer Inc. – Segment focus
Exhibit 70: Pfizer Inc. – Key offerings
Exhibit 71: Pfizer Inc. – Key customers
Exhibit 72: Sanofi – Vendor overview
Exhibit 73: Sanofi – Business segments
Exhibit 74: Sanofi – Organizational developments
Exhibit 75: Sanofi – Geographic focus
Exhibit 76: Sanofi – Segment focus
Exhibit 77: Sanofi – Key offerings
Exhibit 78: Sanofi – Key customers
Exhibit 79: Validation techniques employed for market sizing



【掲載企業】

Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、Pfizer Inc.、and Sanofi

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[胆管癌治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆